Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have advanced Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination chemotherapy regimens in treating patients who have advanced Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABVD regimen | Drug | — | UNRESOLVED |
| bleomycin sulfate | Biological | Bleomycin | ALIAS |
| dacarbazine | Drug | Dacarbazine | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| mechlorethamine hydrochloride | Drug | Mechlorethamine | ALIAS |
| prednisone | Drug | Prednisone | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Relapse-free survival
Secondary outcomes (2)
- measure
- Overall survival
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed Hodgkin's lymphoma (any sub-type) * Stage IB, IIB, IIIA, IIIB, or IV OR * Stage IA or IIA with locally extensive disease (e.g., bulky mediastinal disease (e.g., greater than 0.33 of the maximum transthoracic diameter on routine chest X-ray or at least 2 extranodal sites of disease)) PATIENT CHARACTERISTICS: Age: * 18 to 60 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Complete blood count normal unless directly due to Hodgkin's lymphoma Hepatic: * Hepatic function normal unless directly due to Hodgkin's lymphoma Renal: * Renal function normal unless directly due to Hodgkin's lymphoma Cardiovascular: * No pre-existing cardiac disease Pulmonary: * No pre-existing pulmonary disease Other: * Not pregnant * Fertile patients must use effective contraception during and for six months after study * HIV negative * No other prior malignancy except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No prior therapy for Hodgkin's lymphoma
References
Publications (0)
Data not yet available